+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cancer Cachexia Pipeline Analysis and Outlook, 2019

  • ID: 4772463
  • Report
  • May 2019
  • Region: Global
  • 92 pages
  • VPA Research
1 of 3


  • AAVogen Inc
  • Aeterna Zentaris Inc
  • AVEO Oncology
  • RaQualia Pharma Inc
  • StemMed Ltd
  • Teijin Pharma Ltd
  • MORE
Cancer Cachexia pipeline

Cancer Cachexia pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Cancer Cachexia R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Cancer Cachexia report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Cancer Cachexia as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Cancer Cachexia with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Cancer Cachexia pipeline Profiled in detail

Key players actively participating in Cancer Cachexia pipeline are profiled along with their R&D progress in Cancer Cachexia treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Cancer Cachexia pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Cancer Cachexia treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Cancer Cachexia pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Cancer Cachexia pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Cancer Cachexia pipeline study
  • All recent news and developments related to Cancer Cachexia drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • AAVogen Inc
  • Aeterna Zentaris Inc
  • AVEO Oncology
  • RaQualia Pharma Inc
  • StemMed Ltd
  • Teijin Pharma Ltd
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Cancer Cachexia Disease Overview

3. Cancer Cachexia Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Cancer Cachexia Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Cancer Cachexia Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Cancer Cachexia companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Cancer Cachexia Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • AAVogen Inc
  • Abreos Biosciences Inc
  • Aeterna Zentaris Inc
  • Aphios Corp
  • AVEO Oncology
  • Energenesis Biomedical Co Ltd
  • Extend Biosciences Inc
  • Helsinn Healthcare SA Incyte Corporation
  • NGM Biopharmaceuticals Inc
  • Paradigm Biopharmaceuticals Ltd
  • RaQualia Pharma Inc
  • Signablok Inc
  • StemMed Ltd
  • TCI Peptide Therapeutics
  • Teijin Pharma Ltd
  • Vascular BioSciences
  • Viking Therapeutics Inc
  • XBiotech Inc
  • Zeria Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown